Category Archives: Cell Medicine

Public release date: 12-Jun-2012 [ | E-mail | Share ] Contact: Steve Yozwiak syozwiak@tgen.org 602-343-8704 The Translational Genomics Research Institute SCOTTSDALE, Ariz. June 12, 2012 Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine. Vismodegib (marketed under the name Erivedge) was administered for the first time in the world on Jan. 23, 2007 in a Phase I clinical trial at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen). This is the first drug tested under the Scottsdale Healthcare-TGen partnership to receive FDA approval, and is the first to receive FDA approval to treat inoperable basal cell carcinoma. Successful early trial results led to additional study sponsored by Genentech. The successful Phase I study at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, headed by Scottsdale Healthcare Chief Scientific Officer and TGen Physician-In-Chief Daniel Von Hoff, M.D, led to a broader study, published June 7 … Continue reading →

Public release date: 12-Jun-2012 [ | E-mail | Share ] Contact: Steve Yozwiak syozwiak@tgen.org 602-343-8704 The Translational Genomics Research Institute SCOTTSDALE, Ariz. June 12, 2012 Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine. Vismodegib (marketed under the name Erivedge) was administered for the first time in the world on Jan. 23, 2007 in a Phase I clinical trial at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen). This is the first drug tested under the Scottsdale Healthcare-TGen partnership to receive FDA approval, and is the first to receive FDA approval to treat inoperable basal cell carcinoma. Successful early trial results led to additional study sponsored by Genentech. The successful Phase I study at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, headed by Scottsdale Healthcare Chief Scientific Officer and TGen Physician-In-Chief Daniel Von Hoff, M.D, led to a broader study, published June 7 … Continue reading →

11-06-2012 10:25 Research & Compilation : by (Me) Nicholas Ellis @ "Everyone should consider his body as a priceless gift from one whom? he loves above all, a marvelous work of art, of indescribable beauty, and mystery? beyond human conception, and so delicate that a word,?? a breath, a look, nay, a thought may injure it."- Nikola Tesla "A human being is a microcosmos, ie the laws prevailing in the cosmos also operate in the minutest space of the human being."- Viktor Schauberger Note: fMRI's / Cardiopulmonary Capillary Hemo Dynamics, and its relationship with Magnetoencephalography Note: Cold-Core Eddy Current vs Warm-Core Eddy Current and its relationship with Thermohaline Circulation Systems "Electricians are now admitting that, in electric currents the energy does not flow through, or along the wire, itself; but is actually transmitted by the ether vibrations outside of the wire,"-John Keely Most people know that nerves work by passing electrical currents from cell to cell. But you might be surprised to learn that no one knows exactly how anesthetics stop nerves from carrying pain signals. That's why two scientists believe that we really don't know how nerves work after all. According to their controversial theory, electricity is just a … Continue reading →

11-06-2012 13:32 Download this and other presentations for FREE from Examville's Study Aids section. View thousands of videos and download study aids and tutorials at (consumer-to-consumer education marketplace). Upload your videos and study aids and host your own classes/tutoring sessions for free at Examville. Join for FREE - Examville.com® - the education marketplace (TM). Read the original post: Cell Membranes - The Fluid Mosaic Model (Examville) - Video … Continue reading →

CARLSBAD, Calif., June 12, 2012 /PRNewswire/ -- Life Technologies Corporation (LIFE) today announced a partnership with Cellular Dynamics International (CDI), the world's largest producer of human cells derived from induced pluripotent stem (iPS) cells, to commercialize a set of three new products optimized to consistently develop and grow human iPS cells for both research and bioproduction. The partnership marries CDI's leadership in human iPS cell development with Life Technologies' expertise in stem cell research tool manufacturing and global distribution network to make these novel technologies accessible to researchers around the world. Life Technologies' commercialization of Essential 8 Medium, Vitronectin (VTN-N), and Episomal iPSC Reprogramming Vectors addresses several challenges associated with developing relevant cells for use in a wide range of studies, from basic and translational research to drug discovery efforts. The effectiveness of these products is the focus of recent validation studies published in the journals Nature Methods and PLoS One. "The launch of these new stem cell culture products furthers CDI founder and stem cell pioneer Jamie Thomson's vision to enable scientists worldwide to easily access the power of iPSC technology, thus driving breakthroughs in human health," noted Bob Palay, CDI Chief Executive Officer. To eliminate the variability introduced … Continue reading →

09-06-2012 20:50 The telomeres and telomerase Medicine 2009 Nobel Prize in physiology telomer khavinson npcriz peptid bioregulators The telomeres or telomere of the chromosomes forming DNA at the end of short, repeated thousands of times more sections, which are about protecting them from destruction, from falling apart. TTAGGG in humans and mammalian animals the code is repeated thousands of times, this sequence represents approximately 20 to 25000 base pairs. The cells (and thus the whole organism) élettatalmát determined. Each nucleus of somatic cells with 2n, ie, 46 pairs of chromosomes in this organism as a whole make up the DNA molecules encoding can be found. Shorter or longer cells are divided in sections (except for example. The nerve cells). This genetic material to be kett?z?dnie (S phase). Each doubling of the chromosomal DNA after a few base pairs shorter. The amount is about. 100 basis, because the DNA is responsible for copying the operating mechanism of DNA polymerase enzymes. While the non-coding genes teloméra shorter section of DNA is not damaged, the longer is the region's more teloméra division failure can occur without damage and it's easy to see: that much longer we can live as healthy cells. The human … Continue reading →

Editor's Choice Main Category: Cancer / Oncology Article Date: 11 Jun 2012 - 11:00 PDT Current ratings for: 'Vismodegib For Treatment Of Patients With Basal Cell Carcinoma' The study, published in the New England Journal of Medicine (NEJM), found that vismodegib healed visible lesions or shrank tumors in 30% of patients whose cancer had metastasized and in 43% of patients with locally advanced BCC. Although BCC is the most prevalent type of skin cancer in Europe, there are currently no approved drugs for advanced BCC available in the UK. BCCs, which almost always occur on parts of the body excessively exposed to the sun, can cause disfigurement if not treated promptly and can also develop into a potentially life threatening advanced form of BCC. Dr John Lear, Consultant Dermatologist at Manchester Royal Infirmary, explained: According to the researchers, 9.5 months was the median duration of progression-free survival (PFS) among patients taking vismodegib. In addition, they found that the most common side effects included: Written By Grace Rattue Copyright: Medical News Today Not to be reproduced without permission of Medical News Today MLA Grace Rattue. "Vismodegib For Treatment Of Patients With Basal Cell Carcinoma." Medical News Today. MediLexicon, Intl., 11 Jun. … Continue reading →

Public release date: 11-Jun-2012 [ | E-mail | Share ] Contact: Susan Martonik smartonik@snm.org 703-652-6773 Society of Nuclear Medicine Miami Beach, Fla.Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting explores treatment with a newly developed type of radioimmunotherapy used for treating a resistant form of kidney cancer. The agent is able to hone in on the disease, called clear cell renal carcinoma, and kill the cancer by delivering radiation directly to it. However, the study shows that its effectiveness could be diminished when used after another anti-cancer therapy. The radioimmunotherapy highlighted in this study is radiolabeled monoclonal antibody girentuximab (also known as cG250), a potent anticancer therapy that delivers a precise and powerful dose of radiation just at the site of cancerous tissues. Theobjective of the study was to investigate the effect of the widely used tyrosine kinase inhibitor (TKI) on the targeting of In-111-cG250 in clear cell renal cancer patients. "This research has important implications for future therapeutic regimens for patients with clear cell renal carcinoma," says Stijn Muselaers, M.D., lead physician of the study at Radboud University Nijmegen Medical Centre in Nijmegen, The Netherlands. "This study indicates that imaging and therapy of tumors with radiolabeled … Continue reading →

Public release date: 11-Jun-2012 [ | E-mail | Share ] Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Health Sciences UCLA stem cell scientists purified a subset of stem cells found in fat tissue and made from them bone that was formed faster and was of higher quality than bone grown using traditional methods, a finding that may one day eliminate the need for painful bone grafts that use material taken from the patient during invasive procedures. Adipose, or fat, tissue is thought to be an ideal source of cells called mesenchymal stem cells - capable of developing into bone, cartilage, muscle and other tissues - because they are plentiful and easily attained through procedures such as liposuction, said Dr. Chia Soo, vice chair for research at UCLA Plastic and Reconstructive Surgery. The co-senior authors on the project, Soo and Bruno Pault, are members of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Traditionally, cells taken from fat had to be cultured for weeks to isolate the stem cells which could become bone, and their expansion increases risk of infection and genetic instability. A fresh, non-cultured cell composition called stromal … Continue reading →

ScienceDaily (June 11, 2012) A customized patch treatment for basal cell carcinoma completely destroys facial tumors without surgery or major radiation therapy in 80 percent of patients studied, say researchers at the Society of Nuclear Medicine's 2012 Annual Meeting. There are two main types of skin cancer:melanoma, which forms deep in the cells that produce pigment in skin, and nonmelanoma cancer, such as basal cell carcinoma and squamous cell carcinoma. Basal cell carcinoma is the most common type of skin cancer that affects the surface layer of the skin. Researchers have developed a treatment called a phosphorus-32 (P-32) skin patch, a radiation spot-treatment in the form of a patch that can safely and easily kill skin tumors with a few easy outpatient appointments. This therapy is ideal for patients with skin cancers that are very difficult to operate on, especially if skin grafting after surgery would be a challenge. "The study is important for the field of nuclear medicine as it opens a new dimension in the field of therapeutic nuclear medicine and dermatology, especially for the treatment of skin malignancies," says Priyanka Gupta, Ph.D., the lead of author of the study at All India Institute of Medical Sciences, New … Continue reading →